CC
MED icon

Cypress Capital’s Medifast MED Stock Holding History

Cypress Capital’s Portfolio MED Stock Details MED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-19
Closed -$415 – 240
2024
Q2 		$415 Buy
+19
New +$506 ﹤0.01% 360

Other funds holding MED

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cypress Capital's MED Position: Q3 2024 in Review

Cypress Capital sold out of Medifast (MED) in Q3 2024, closing a stake of 19 shares — an estimated $415 sold.

Cypress Capital first reported a position in MED in Q2 2024 and held it in 1 quarter. The position peaked at $415 in Q2 2024. 140 funds tracked by Wall St. Rank hold MED as of Q3 2024.

  • Cypress Capital reported no remaining Medifast position as of Q3 2024 after selling out during the quarter.
  • Cypress Capital sold 19 Medifast shares in Q3 2024, an estimated $415.
  • Cypress Capital first reported a position in Medifast in Q2 2024 and held it in 1 quarter.
  • Cypress Capital's Medifast position peaked at $415 in Q2 2024.
  • 140 funds tracked by Wall St. Rank held Medifast as of Q3 2024.

Based on Cypress Capital's 13F filing for Q3 2024, filed 12 Nov 2024.